The introduction of Cupron technology into the global consumer and healthcare markets is a major focus of the expanded management team; and led to the formation of Cupron Medical Inc., stated Paul Rocheleau. Over the past five years Cupron has refined the technology ™s performance and clinically demonstrated efficacy in a wide range of healthcare applications, said Paul. We now have the knowledge, financing and the team to commercialize our technology into a wide range of healthcare products. This will provide important new tools for caregivers to utilize against both the growing problem of Hospital Acquired Infections and the care of patients afflicted with certain disease states such as diabetes or medical issues such as chronic wounds. An estimated 6 million Hospital Acquired Infections occur each year across the United States, Europe and Japan. In the US alone, there are nearly 100,000 deaths annually, with treatment costs estimated in the tens of billions of dollars.

The proceeds from the transaction are being used to expand new product development and the clinical trial program, gain additional regulatory approvals, and significantly strengthen and expand the global management and sales teams to support a higher level of commercialization activity. Both Cupron Inc. and Cupron Medical Inc. are in the process of launching a number of new products, both independently and in conjunction with strategic partners worldwide.

SOURCE Virginia Life Sciences Investments, LLC